Fierce Pharma
MARCH 6, 2024
AstraZeneca CEO Pascal Soriot, who has been critical of the U.K.’s business environment for the life sciences industry, is directing a big chunk of money into the Big Pharma’s home country. | AstraZeneca CEO Pascal Soriot, who has been critical of the U.K.’s business environment for the life sciences industry, is directing £650 million into the Big Pharma’s home country.
MedCity News
MARCH 6, 2024
Immersive scenarios in VR allow nursing education programs to enhance and scale the hands-on experiences they provide learners for developing and practicing critical skills.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
MARCH 6, 2024
Two biosimilars to Amgen’s lucrative bone drugs Prolia and Xgeva have clinched approvals at the FDA, though ongoing patent litigation makes launch timing uncertain. | Sandoz has clinched FDA approvals for biosimilars to Amgen’s denosumab. Sandoz’s drugs mark the first approved denosumab biosimilars and treat all indications of the reference products.
MedCity News
MARCH 6, 2024
This case, about the claim that Merck failed to warn patients about the risk of typical femoral fracture, reaches past this suit to potentially change pharmaceutical companies’ relationship with the FDA.
Fierce Pharma
MARCH 6, 2024
GSK's antiretroviral HIV medicine Tivicay (dolutegravir) has been recommended by the World Health Organization since 2018 as a preferred treatment for the virus. | The World Health Organization (WHO)'s latest HIV Drug Resistance report showed that some patients are developing resistance to Tivicay, which has been recommended as a preferred treatment since 2018.
MedCity News
MARCH 6, 2024
At ViVE, investors and health system executives shared their biggest pet peeves when it comes to pitches from digital health startups.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
MARCH 6, 2024
A panel discussion of hospital executives at the ViVE event last month offered insight into the challenges of implementing innovation and what they have learned from their experiences.
pharmaphorum
MARCH 6, 2024
A £650 million investment package by AstraZeneca in the UK has been held up by Chancellor Jeremy Hunt as a “vote of confidence” in the country’s life sciences sector. AZ is preparing to invest £450 million at its manufacturing site in Speke, Liverpool, to boost research, development and manufacturing of vaccines, including the construction of a new plant that will be powered by renewable energy, according to a government statement.
MedCity News
MARCH 6, 2024
Women’s health advocates overwhelmingly came out in support of the White House’s $100 million investment into women’s health research. However, some noted shortcomings in where the funding is going.
Pharmaceutical Technology
MARCH 6, 2024
Demand for medicinal cannabis is increasing globally to treat a range of illnesses and conditions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
European Pharmaceutical Review
MARCH 6, 2024
The US Food and Drug Administration (FDA) has approved the first and only FDA-approved denosumab biosimilars, to treat all indications of the reference medicines. This means that Sandoz ’s Wyost ® (denosumab-bbdz) and Jubbonti ® (denosumab-bbdz) are interchangeable for all indications of reference medicines Xgeva ® (denosumab) and Prolia ® (denosumab).
MedCity News
MARCH 6, 2024
Will 2024 bring any change, or will we witness yet another record- and heart-breaking year of preventable deaths?
pharmaphorum
MARCH 6, 2024
NICE has turned down Sanofi’s Xenpozyme as a treatment for the rare disease acid sphingomyelinase deficiency (ASMD), creating a situation where access to the drug in the UK will depend on a patient’s address.
MedCity News
MARCH 6, 2024
Gilead Sciences’ partnership with Merus could yield novel antibody drugs capable of binding to three targets simultaneously. The alliance follows a collaboration that Gilead started last year with Tentarix Biotherapeutics, a startup also developing antibodies that bind to multiple targets.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
MARCH 6, 2024
Sandoz has claimed the first FDA approvals for biosimilars of Amgen’s blockbuster bone disease therapy denosumab, but has not said when it plans to launch them onto the US market.
PharmaVoice
MARCH 6, 2024
Innovation in schizophrenia has been slow, and patients are often left with few options — but pharmas contribute to a robust lineup of candidates that could improve care.
Pharmaceutical Technology
MARCH 6, 2024
J&J submitted a new application to the EMA for the approval of its Darzalex combination therapy for multiple myeloma.
Healthcare Success
MARCH 6, 2024
Whether you run a multilocation healthcare organization, hospital, or health system, understanding the distinction between search engine optimization (SEO) vs. search engine marketing (SEM)—and how each distinctly helps your business—is important for several reasons. This knowledge helps you: Allocate resources more efficiently. Tailor marketing initiatives to align with specific goals.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
pharmaphorum
MARCH 6, 2024
Bayer CEO says company is “badly broken” by patent losses, litigation, debt levels, and bureaucracy, limiting its options for a break-up of the group.
PharmaTimes
MARCH 6, 2024
The project will train a newly developed AI system on data collected from participating men and women
Pharmaceutical Technology
MARCH 6, 2024
Experience rapid pain relief with Sorrento Therapeutics' stable oral liquid pharmaceutical composition of celecoxib. Patent filed for effective pain management within 2 hours.
PharmaTimes
MARCH 6, 2024
CDH affects one in 5,000 babies born in the UK, impacting the foetus’ development of vital organs
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharmaceutical Technology
MARCH 6, 2024
Discover Avacta Group's groundbreaking patent for therapeutic conjugates with extended half-life, targeting improved efficacy in treating diseases like cancer. Learn more about this innovative approach now!
Pharmaceutical Commerce
MARCH 6, 2024
Navigating the complex landscape of healthcare coverage can be an intimidating task, especially for patients with rare diseases for which treatments often come with a high price tag.
PharmExec
MARCH 6, 2024
In this Pharmaceutical Executive interview, Daniel Ayala, Chief Security and Trust Officer, Dotmatics, dives into the greatest threats to the integrity of data in R&D and threats presented by hackers.
MedCity News
MARCH 6, 2024
At the ViVE event in Los Angeles last month, health tech executives shared how their companies are putting innovative ideas into action to address the most pressing needs in healthcare, as part of the Vibe at ViVE by MedCity News.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Clarivate
MARCH 6, 2024
For 13 years, Clarivate has identified the organizations leading the world in technology research and innovation. As the pace of innovation continues to accelerate and competition intensifies, we introduce the Top 100 Global Innovators 2024. This year, ranked. 2024 report key findings Samsung Electronics ranks first in the Top 100 Global Innovators 2024.
PharmaVoice
MARCH 6, 2024
An all-out blitz across U.S. courts is bolstering pharma’s goal to overturn Medicare drug price negotiations.
Zymewire
MARCH 6, 2024
Best practices for crafting effective cold outreach messages to biotech and pharma companies as we go up against AI (ChatGPT) in a could outreach face off
Pharmaceutical Technology
MARCH 6, 2024
Sonrai Analytics has entered a partnership with Candel to expedite the development of viral immunotherapies for treating cancer.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
317 
Let's personalize your content